Danaher stock: CEO sets 4%-5% 2027 growth base, eyes faster expansion

Published on 11/11/2026 at 12:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Danaher stock is entering a new phase under CEO Julie Sawyer Montgomery. Her plan centers on execution, innovation, talent and disciplined capital allocation.

Growth plan centers on execution

CEO Julie Sawyer Montgomery named commercial execution, innovation, talent and capital allocation as the main growth levers.
Danaher expects share gains, new products and cross-selling to support a move toward high-single-digit growth over several years.
Reshoring, artificial intelligence and diagnostics are central to the company's longer-term expansion case.

Danaher Corp., US2358511028, Illustration mit AI erstellt.

Danaher is setting a new growth agenda under CEO Julie Sawyer Montgomery after her appearance at the UBS Global Healthcare Conference on Monday, November 9. Investing.com reported that management sees 4% to 5% core growth excluding respiratory revenue as the starting point for 2027.

Montgomery said Danaher wants to move from a mid-single-digit growth base toward high-single-digit growth over the next several years. She identified commercial execution, innovation, talent and capital allocation as the four main levers, while emphasizing market-share gains and sustainable profitability.

Execution will test the strategy

The strategy calls for broader cross-selling across Danaher's operating companies and more consistent use of the Danaher Business System after acquisitions. Montgomery also described disciplined mergers and acquisitions as a priority, but said the company would walk away from transactions that do not offer a credible path to differentiated growth.

Several businesses provide the operating backdrop for that plan. Management highlighted improving momentum at Cytiva, SCIEX, Abcam and IDT, while saying Cepheid continues to grow at a double-digit rate outside respiratory testing. Danaher also pointed to China, where third-quarter growth was in the high-single-digit range overall, with stronger performance in biotechnology.

Longer-term opportunities remain uneven

Danaher sees biologics, biosimilars, AI-enabled drug discovery and blood-based Alzheimer's testing as structural opportunities. The company also estimates a reshoring opportunity in bioprocessing, but Montgomery said the main revenue benefit is more likely to emerge from 2028 onward. Cytiva equipment orders grew at a mid-teens rate in the third quarter, with management expecting conversion into revenue over nine to 12 months.

For investors, the key test is whether the preliminary growth base turns into stronger reported performance. Montgomery said shareholders should watch for higher core growth, clear share gains and improved value creation over the next three to five years.

Danaher stock traded at 210.30 euros on Lang & Schwarz at 12:37 CET on Wednesday, November 11, 2026.